

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated April 23, 2018 (the “**Prospectus**”) issued by Ping An Healthcare and Technology Company Limited (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.*

*Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.*

## **PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED**

**平安健康醫療科技有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1833)**

## **STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF OVER-ALLOTMENT OPTION**

### **STABILIZING ACTIONS AND END OF STABILIZATION PERIOD**

The Company announces that the stabilization period in connection with the Global Offering ended on May 26, 2018, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

Further information of stabilizing actions undertaken by UBS AG Hong Kong Branch, the Stabilizing Manager, its affiliates or any person acting for it during the stabilization period is set out in this announcement.

### **LAPSE OF OVER-ALLOTMENT OPTION**

The Joint Global Coordinators did not exercise the Over-allotment Option during the stabilization period and the Over-allotment Option lapsed on May 26, 2018.

## **STABILIZING ACTIONS AND END OF STABILIZATION PERIOD**

The Company announces that the stabilization period in connection with the Global Offering ended on May 26, 2018, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by UBS AG Hong Kong Branch, the Stabilizing Manager, its affiliates or any person acting for it during the stabilization period are set out below:

- (i) over-allocation of an aggregate of 24,014,100 Shares in the International Offering, representing approximately 15% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option;
- (ii) successive purchases of an aggregate of 24,014,100 Shares in the price range of HK\$48.90 to HK\$54.80 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the market during the stabilization period. The last purchase made by the Stabilization Manager on the market during the stabilization period was on May 24, 2018 at the price of HK\$50.50 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

## **LAPSE OF OVER-ALLOTMENT OPTION**

The Joint Global Coordinators did not exercise the Over-allotment Option during the stabilization period and the Over-allotment Option lapsed on May 26, 2018.

## **PUBLIC FLOAT**

Immediately following the completion of the Global Offering, assuming the options granted under the Employee Incentive Scheme remain unexercised, the Company will continue to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules.

By order of the Board  
**Ping An Healthcare and Technology Company Limited**  
**Mr. Wang Tao**  
*Chairman*

Hong Kong, May 27, 2018

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Wang Tao as Chairman and Executive Director, Mr. Lee Yuan Siong, Mr. Yao Jason Bo, Ms. Cai Fangfang, Mr. Dou Wenwei, Ms. Wang Wenjun and Mr. Law Siu Wah Eddie as Non-executive Directors, and Mr. Tang Yunwei, Mr. Guo Tianyong, Mr. Liu Xin and Mr. Chow Wing Kin Anthony as Independent Non-executive Directors.*